Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupadolimab (CPI-006) in Advanced Cancers
NCT03454451Phase 1Completed
- Sponsor
- Corvus Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of mupadolimab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal cancer (CRC) and 10 more (6 arms), sponsored by Corvus Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities up to 36 months, Incidence of treatment-emergent adverse events up to 36 months and 1 more. Started Apr 2018; status: completed.
02
Drugs
mupadolimab
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)colorectal cancer (CRC)triple-negative breast cancer (TNBC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03454451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454451.